BioCentury | Jun 5, 2018
Distillery Techniques

Drug platforms

...available for licensing or partnering from Integral Molecular Inc.; platform available for partnering PUBLICATION DETAILS: Tucker...
BioCentury | Mar 17, 2015
Company News

Management tracks

...was CMO at Acorda Therapeutics Inc. (NASDAQ:ACOR). Oncology company Deciphera Pharmaceuticals LLC (Lawrence, Kan.) named Tucker...
BioCentury | Feb 13, 2014
Targets & Mechanisms

A RIPping target in Gaucher's disease

...Fund , Granite Bay, Calif. Genzyme Corp. , Cambridge, Mass. National Gaucher Foundation Inc. , Tucker...
BioCentury | Oct 17, 2013
Distillery Techniques

Technology: Disease models

...retinal disorders. SciBX 6(40); doi:10.1038/scibx.2013.1141 Published online Oct. 17, 2013 Patent and licensing status unavailable Tucker...
BioCentury | Jun 17, 2013
Company News

BioLineRx, Jiangsu Chia-Tai Tianqing deal

...high single-digit royalties. BioLineRx in-licensed the compound from Genoscience (Marseille, France) and RFS Pharma LLC (Tucker...
BioCentury | Jun 11, 2013
Company News

BioLineRx out-licenses HCV compound to Jiangsu Chia-Tai

...be reached for details, in-licensed the compound from Genoscience (Marseille, France) and RFS Pharma LLC (Tucker...
BioCentury | Jan 17, 2013
Targets & Mechanisms

Overcoming amantadine resistance

...to potentially resurrect the older amantadine class of drug is a worthy goal," said Simon Tucker...
BioCentury | May 14, 2012
Company News

Incline Therapeutics management update

...Incline Therapeutics Inc. , Redwood City, Calif. Business: Neurology Hired: John Tucker as SVP and chief...
BioCentury | Apr 5, 2012
Cover Story

MRSA sensitivity training

...surprising and might, for example, lead to potentially resurrecting penicillin compounds for MRSA," said Simon Tucker...
...infections, said Tucker. Those new inhibitors are of a different chemical class than PC190723, although Tucker...
BioCentury | Mar 5, 2012
Company News

Pfizer, Alacer Corp. deal

...supplement portfolio. Lazard and Houlihan Lokey were financial advisors, while DLA Piper and Rutan & Tucker...
Items per page:
1 - 10 of 90
BioCentury | Jun 5, 2018
Distillery Techniques

Drug platforms

...available for licensing or partnering from Integral Molecular Inc.; platform available for partnering PUBLICATION DETAILS: Tucker...
BioCentury | Mar 17, 2015
Company News

Management tracks

...was CMO at Acorda Therapeutics Inc. (NASDAQ:ACOR). Oncology company Deciphera Pharmaceuticals LLC (Lawrence, Kan.) named Tucker...
BioCentury | Feb 13, 2014
Targets & Mechanisms

A RIPping target in Gaucher's disease

...Fund , Granite Bay, Calif. Genzyme Corp. , Cambridge, Mass. National Gaucher Foundation Inc. , Tucker...
BioCentury | Oct 17, 2013
Distillery Techniques

Technology: Disease models

...retinal disorders. SciBX 6(40); doi:10.1038/scibx.2013.1141 Published online Oct. 17, 2013 Patent and licensing status unavailable Tucker...
BioCentury | Jun 17, 2013
Company News

BioLineRx, Jiangsu Chia-Tai Tianqing deal

...high single-digit royalties. BioLineRx in-licensed the compound from Genoscience (Marseille, France) and RFS Pharma LLC (Tucker...
BioCentury | Jun 11, 2013
Company News

BioLineRx out-licenses HCV compound to Jiangsu Chia-Tai

...be reached for details, in-licensed the compound from Genoscience (Marseille, France) and RFS Pharma LLC (Tucker...
BioCentury | Jan 17, 2013
Targets & Mechanisms

Overcoming amantadine resistance

...to potentially resurrect the older amantadine class of drug is a worthy goal," said Simon Tucker...
BioCentury | May 14, 2012
Company News

Incline Therapeutics management update

...Incline Therapeutics Inc. , Redwood City, Calif. Business: Neurology Hired: John Tucker as SVP and chief...
BioCentury | Apr 5, 2012
Cover Story

MRSA sensitivity training

...surprising and might, for example, lead to potentially resurrecting penicillin compounds for MRSA," said Simon Tucker...
...infections, said Tucker. Those new inhibitors are of a different chemical class than PC190723, although Tucker...
BioCentury | Mar 5, 2012
Company News

Pfizer, Alacer Corp. deal

...supplement portfolio. Lazard and Houlihan Lokey were financial advisors, while DLA Piper and Rutan & Tucker...
Items per page:
1 - 10 of 90